Hamlet BioPharma Expands Clinical Trials for Bladder Cancer Treatment with University of Iowa Collaboration

Hamlet BioPharma Expands Clinical Trials for Bladder Cancer

In a significant advancement in bladder cancer treatment, Hamlet BioPharma AB has announced a collaboration with the University of Iowa, forming a new partnership aimed at tackling high-risk, non-muscle-invasive bladder cancer (NMIBC), particularly the Carcinoma In Situ (CIS) variant. This innovative clinical trial, backed by findings from previous research, focuses on an experimental treatment known as Alpha1H, derived from human breast milk. This phase of research is crucial as it directly addresses a substantial unmet medical need in a patient population suffering from resistant and severe forms of bladder cancer.

Collaboration and Research Background

The agreement between Hamlet BioPharma and the University of Iowa, led by prominent figure Professor Michael O'Donnell, highlights the institution's reputation in the field of bladder cancer research. This partnership aims to utilize the success of Alpha1H, previously evaluated through early-stage clinical studies, to explore its potential in treating CIS, a form of bladder cancer that is notorious for its resistance to conventional therapies.

CIS is a flat, high-grade carcinoma that can lead to serious health complications if left untreated. The traditional treatment using Bacillus Calmette-Guérin (BCG) immunotherapy has proven effective for many, but a significant percentage of patients—estimated between 30% to 50%—do not respond well or relapse, thus necessitating new therapeutic approaches.